UNSPSC 51332846: Cyamemazine tartrate

This classification denotes a histamine-1 receptor antagonist C19H21N3S.C4H6O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier C4ZT3BE459, chemically known as 10h-phenothiazine-2-carbonitrile, 10-(3-(dimethylamino)-2-methylpropyl)-, (2r,3r)-2,3-dihydroxybutanedioate (1:1), but more generally known as cyamemazine tartrate, which bears US NIH Compound Identifier 24892868. European Medicines Agency schedules Cyamemazine tartrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01510MIG.

Most nations, for tariff and trade purposes, schedule cyamemazine tartrate under HS 29343090 and SITC 51578. As of Q4 2014, CYAMEMAZINE TARTRATE remains US FDA's Preferred Term for this commodity. SMILES: CC(CN1C2CCCCC2SC3C1CC(CC3)C#N)CN(C)C.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O.

UNSPSC 51332846 Cyamemazine tartrate (Commodity) shows minimal recent state and local procurement activity. The code nominally covers a specific pharmaceutical compound used in psychiatric treatment, but the one recent solicitation on record—Seminole County, Florida's IFB60459723LAS, posted June 30, 2026—procurement targets naloxone and drug deactivation systems for community health initiatives, which falls outside the code's pharmaceutical-class scope. The mismatch suggests either a tagging error in the source database or a misalignment between the code's intended use and how jurisdictions are applying it in practice.

Seminole County's IFB sought 1,900 units of naloxone and 800 safe drug deactivation systems annually through an electronic bid process, with a July 26, 2023 response deadline and quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. The contract carried a two-year initial term with one-year renewal option, fixed-fee pricing, and standard compliance requirements including drug-free workplace certification, E-Verify, and potential FEMA-related federal regulations. Given the absence of additional solicitations under the code and the lack of alignment between the code's stated commodity and the actual procurement, this code presents limited pursuit opportunity for vendors focused on cyamemazine tartrate or related pharmaceutical products at the state and local level.